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AIM: To provide a systematic review, of published data, to compare weight losses following very low calorie (o800 kcal per day
VLCD) or low-energy liquid-formula (4800 kcal per day LELD) diets, in people with and without type 2 diabetes mellitus (T2DM).
METHODS: Systematic electronic searches of Medline (1946–2015) and Embase (1947–2015) to identify published studies using
formula total diet replacement diets (VLCD/LELD). Random effects meta-analysis using weighted mean difference (WMD) in body
weight between groups (with and without diabetes) as the summary estimate.
RESULTS: Final weight loss, in the five included studies, weighted for study sizes, (n= 569, mean BMI = 35.5–42.6 kg/m2), was not
significantly different between participants with and without T2DM: − 1.2 kg; 95% CI: − 4.1 to 1.6 kg). Rates of weight loss were also
similar in the two groups − 0.6 kg per week (T2DM) and 0.5 kg per week (no diabetes), and for VLCD (o800 kcal per day) and LELD
(4800 kcal per day).
CONCLUSIONS: Weight losses with liquid-formula diets are very similar for VLCD and LELD and for obese subjects with or without
T2DM. They can potentially achieve new weight loss/ maintenance targets of 415–20% for people with severe and medically
complicated obesity.
International Journal of Obesity (2017) 41, 96–101; doi:10.1038/ijo.2016.175
INTRODUCTION
As populations become more obese, there is increasing concern
about the rapidly rising categories of severe obesity, which
demand greater weight loss to control secondary medical
consequences. Type 2 diabetes mellitus (T2DM) is closely linked
to obesity, and is the main contributor to rising healthcare costs of
obesity.1,2 Most individuals with T2DM have a BMI425 kg/m2 and
about half have a BMI 430 kg/m2.2–4 With a BMI over 35 kg/m2,
20% of all men and 11% of women have known diabetes.5
There is overwhelming evidence that modest sustained weight
loss, for example, current target of 5–10%, prevents the onset of
most new T2DM in people with pre-diabetes,6 and that it
improves all aspects of diabetes control (glycaemia, blood
pressure, lipids and microvascular damage7 with reductions in
drug doses for medications used to treat hypertension, diabetes
and dyslipidaemia.8 Although previous guidelines have retained a
5–10% weight-loss target, the 2010 Scottish Intercollegiate (SIGN)
Obesity guideline, recognising changes in obesity prevalence, and
also recent evidence for more aggressive interventions, has set a
new national weight loss/maintenance target of 415–20% for
those with BMI 435 kg/m2 or 430 kg/m2 with serious medical
complications such as T2DM.9 In routine UK National Health
Service diabetes care, few people achieve a weight loss of415 kg
(or 415%). Bariatric surgery is recommended for obese people
with T2DM by both the UK National Institute for Care Excellence
(NICE)10 and SIGN,9 and has been shown to reverse the metabolic
abnormalities of T2DM rapidly following surgery, at least in people
up to 6 years after diagnosis of T2DM.11 Surgery carries immediate
and long-term risks, and is not acceptable to all people. The
metabolic benefits of bariatric surgery have been reproduced by
negative energy balance alone, using a low-energy liquid-formula
diets, but these are seldom offered as part of diabetes care.12
With conventional dietary advice, obese people with T2DM
usually lose less weight than people without diabetes, partly
because they have already lost what they can manage, and partly
because many anti-diabetic drugs are obesogenic.13 Here, we
provide a systematic review assessing published studies to
compare weight losses in people with T2DM and people without
diabetes prescribed ‘Total Diet Replacement’ using modern com-
mercial nutrient-replete very-low calorie diets (VLCD,o800 kcal per
day) or low-energy liquid-formula diets (LELD, 4800 kcal per day).
METHODS
This review was conducted following the PRISMA guidelines on
systematic reviews.14
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Data sources and searches
Systematic electronic searches of Medline (1946–2015), Embase
(1947–2015) and CINAHL (1946–2015) were performed to identify
published studies using formula Total Diet Replacement diets. Key
search terms used were: (weight adj2 (loss or lost or losing or
reduce* or change*)), *Obesity/; (type 2 diabetes or non-insulin-
dependent diabetic or non-insulin-dependent diabetes or T2DM);
(low-energy liquid diet or low-energy diet or very-low calorie diet
or liquid-formula diet or calorie restriction or very-low calorie diet).
Hand searching of reference lists of retrieved studies was also
conducted. The search was limited to English language, human
and adults.
Study selection
Articles were selected on the basis of title and abstract. Inclusion
was dependent on the following eligibility criteria: non-
randomised or randomised controlled trial with a primary purpose
of weight management, adult participants (418 years), weight
change reported quantitatively, and a comparison of weight
change in patients with and without T2DM made. Studies
identified by the database searches and review of potentially
relevant studies against inclusion/exclusion criteria were carried
out independently by two reviewers (WL and LH).
Quality assessment
The quality and possible sources of bias of included studies was
independently assessed by two reviewers (WL and LH) using the
Cochrane Risk of Bias Assessment tool for Non-Randomised
Studies of Interventions (ACROBAT-NRSI).15
Data analysis
A random effects meta-analysis was conducted using Compre-
hensive Meta-analysis (CMA; Version 3.0 for Windows). The
weighted mean difference (WMD) in body weight between
participants with T2DM and non-diabetic subjects was used as
the summary estimate. Cochrane’s Q statistic was used to assess
heterogeneity, with the I2 statistic used to measure the degree of
heterogeneity.
Because studies varied in duration, which necessarily affects
total weight loss, a comparison was made between the rates of
weight loss. Mean weekly rate of weight loss was calculated for
each study by dividing mean weight loss by number of study
weeks. Mean rate of weight loss for all studies was calculated by
multiplying mean weekly weight loss for each study by number of
study participants, and then the sum of these figures was divided
by the total number of participants in the group. Where weight
change was reported with s.e.m., this was converted to s.d. (s.e.m.
× √n) to provide consistency in the reported variability.
RESULTS
The systematic search identified 151 potential studies. After
duplicates were removed 121 titles and abstracts were screened.
Obviously irrelevant studies were excluded for the reasons
illustrated in Figure 1. Full texts of 17 studies were retrieved and
reviewed for eligibility against the inclusion/exclusion. Five studies
fulfilled our criteria and were included in the review.
STUDY CHARACTERISTICS
Setting
The studies reported results from USA16,17 Australia,18 UK19 and
Sweden.20 The settings for studies varied. In one study the
intervention was delivered on an inpatient basis,16 one was set in
primary care19 an endocrine clinic,18 obesity clinic17 and surgical
unit.20
Participant demographics
All studies recruited both males and females classified as obese
(BMI430 kg/m2). One study (16) included some people with BMI
425 kg/m2. Mean age ranged from 43 to 55 years.
Exclusion criteria
Exclusion criteria were not described in two studies.19,20 Use of
anti-obesity medications was an exclusion criterion in one study,18
and insulin use in another.16
Medications
Medications used in the management of T2DM were detailed in
three studies18–20 and included metformin, sulphonylurea and
insulin. The prescribed oral hypoglycaemic agents, was not
specified in one study.16 Medications in addition to those for
diabetes management were detailed in two studies.18,19 One
study did not detail medications at all.17
Energy content and duration of formula diets and total diet
replacement
Daily energy provision from the formula diets varied among the
included studies and ranged from 300 to 1000 kcal per day
(Table 1). The durations of VLCD/LELD reported in studies ranged
from 4 to 52 weeks. In one study17 participants transitioned to
include a meal of ~ 300 kcal at different time points.
Quality of included studies
All five included studies were non-randomised (as it is impossible
to randomise into T2DM or non-diabetes categories); two case–
control studies,16,17 one in which participants were allocated to
the treatment of their preference,19 and two cohort studies; one
retrospective17 and one prospective.20 As the studies were dietary
interventions, none included blinding of participants.
Confounding was considered the main possible source of
potential moderate or serious bias in all included studies (Table 2).
Age, gender, baseline weight, and co-morbid conditions are
potential confounders in the achievement of weight loss. Only one
study included adjustments for these factors.17 However in this
study the transition from total meal replacement to partial meal
replacement varied among participants, with a potential influence
on weight loss, and was not adjusted for in analysis. Participant
selection was considered unlikely to have introduced significant
bias, as in all studies those with T2DM were compared with those
without diabetes from the same or similar population. Bias in the
measurement of interventions was low, as in all studies the
intervention was well defined. Outcomes were ascertained using
objective measurements in all studies and therefore the risk of
bias was considered low.
Attrition was reported in two of the five studies,18 and weight
change data were reported for completers only (excluding
dropouts). One study was carried out on an inpatient basis16
and all subjects were included in weight change analyses. In one
study,19 the study population was small, no dropouts were
reported, and we have assumed all subjects were followed up and
included in the analysis. In the remaining study,20 all subjects
completed the study and were included in the weight change
analyses. Risk of bias from missing data was therefore
considered low.
Weight losses
Baseline weights ranged from 99–126 kg (BMI: 30–42.6 kg/m2).
Total weight loss ranged from 8.9 to 15 kg in those with T2DM and
7.9–21 kg in those without diabetes, over treatment durations of
4–-52 weeks.
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The greatest rates of weight loss were mostly in studies with
more restrictive VLCDs.16,19 Study duration did not appear to
influence overall weight loss. Mean weight loss in the study of
longest duration17 was similar, or greater, than that observed in
studies of shorter duration (Table 1).
Meta-analysis
Data allowing meta-analysis (mean weight change (s.d. or s.e.m.)
were available for four studies (Figure 2). Analysis showed almost
identical weight changes (post intervention) in those with and
without diabetes (WMD: − 1.2 kg; 95% CI: − 4.1 to 1.6 kg).
Substantial heterogeneity was observed (I2 = 79%).
Safety
Transient events including constipation, dizziness, postural
hypotension, dry skin and bad breath were reported in two
studies.16,18 Serious adverse events were reported in one study.
Severe hypoglycaemia was experienced by one diabetic patient
using VLCD, and one patient in each group suffered a non-fatal
myocardial infarction.19 The remaining two studies reported that the
intervention/study was completed without any adverse events.17,20
DISCUSSION
Substantial mean weight losses were achieved in all studies
following VLCD/LELD, varying from 8 to 21 kg in total over
4–52 weeks. That total depended on a variety of factors, including
duration of diet, and clinical characteristics of groups, such as age,
gender and status of health. In all the studies, the mean rate of
weight loss fell below that that predicted for 100% compliance
with the estimated energy deficit.
Weight losses were similar for participants with T2DM and
participants without diabetes, with the exception of one study,16
where baseline weight was significantly greater in participants
without diabetes (126.1 ± 8.5 vs 99.7 ± 3.7 kg, Po0.05), which is
likely to have contributed to greater weight loss in the non-
diabetic group.
The data generated on weight loss per week, as studies varied
widely in duration, also showed similar rates of weight loss in
those with T2DM and those without. As with overall weight loss
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Figure 1. Flowchart of progress of papers through the review.
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this was with the exception of the study by Henry et al.16 in which
a greater rate of weight loss was observed in those without
diabetes, again reflecting the higher baseline weight.
The mean weight loss in people with T2DM reported here, in
studies which compared people with T2DM and those without
T2DM, is similar to a previous meta-analysis of VLED in T2DM,
which reported substantial weight loss of 9.6% by people with
T2DM over a 6 week period, at a rate of around 1.6 kg per week.13
Studies using similar diets among only non-diabetic participants
report similar mean weight losses.21–23
Similar weight losses with VLED and LELD have been reported
previously in the study by Christensen et al.21 which compared
VLED and LELD, with weight losses of around 11 kg was observed
in both study groups over 8 weeks. Greater energy restriction also
conferred no additional benefit in the study by Lin et al.22 with a
mean weight loss of 8 kg observed in both groups (450 vs 800 kcal
per day) after 12 weeks. Wikstrand et al.23 reported mean weight
losses of 20 and 16 kg in free living non-diabetic, male and female
participants respectively.
Amongst the studies included in the present review, rates of
weight loss were consistent, at 1.2–3.2 kg per week except for
much lower rates in studies by Li et al.17 0.3 kg per week and Baker
et al.18 0.7 kg per week. The study by Li et al. was over a much
longer period of 52 weeks, and the duration of the exclusive
formula diet phase was variable amongst participants over the 1
year period, as they could opt to include a meal of ~ 300 kcal at
different time points, which may have contributed to the lower
rate of weight loss. Lower weight loss in comparison to other
studies was acknowledged by Baker and colleagues. Factors
suggested by the authors to explain this were a ‘calendar effect’
and also that the study population were well established patients
at a tertiary referral centre and may have represented a more
‘difficult to treat group’ than that of other studies.
The metabolic benefits of bariatric surgery appear to be
reproducible by VLCD/LELD. The Newcastle Counterpoint study12
achieved reversal of T2DM with mean weight loss of 15.3 kg in 11
people with T2DM within 4 years of diagnosis, using a 600 kcal per
day low-energy liquid diet. The normalisation of fasting plasma
glucose persisted for up to 3 months after return to normal diet.T
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Table 2. Risk of bias assessment
Reference Risk of bias
Noren and Forsell
20
Confounding: serious risk
Selection of participants: low risk
Measurement of interventions: low risk
Missing data: low risk
Measurement of outcomes: moderate risk
Li et al.
17
Confounding: moderate risk
Selection of participants: low risk
Measurement of interventions: low risk
Missing data: low risk
Measurement of outcomes: low risk
Baker et al.
18
Confounding: moderate risk
Selection of participants: low risk
Measurement of interventions: low risk
Missing data: low risk
Measurement of outcomes: low risk
Paisey et al.
19
Confounding: serious risk
Selection of participants: moderate risk
Measurement of interventions: low risk
Missing data: low risk
Measurement of outcomes: low risk
Henry et al.
16
Confounding: serious risk
Selection of participants: no information
Measurement of interventions: low risk
Missing data: low risk
Measurement of outcomes: low risk
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Normalisation of HbA1c, or fasting blood glucose, following
VLCD was reported in one study included in the present
review, Paisey et al.19 with mean absolute weight loss similar to
that achieved by Lim et al.12 However normalisation of metabolic
status relates both to ongoing energy restriction and on overall
weight loss. Acute energy restriction has been shown to improve
plasma glucose values and insulin sensitivity even before
significant weight loss occurs.12,13
Formula diets, with a period of total diet replacement, are
widely used and popular outside healthcare settings. There is
some published evidence that they are successful, with little or no
evidence for serious safety problems,24 although large-scale safety
testing has not been undertaken. The serious adverse events
reported in one study included in the present review were not
considered directly related to the diet. Despite clear evidence for
efficacy and lack of safety concerns, there is a continuing
reluctance by medical staff and in clinical guidelines to support
the use of formula diets. Guidelines published in the USA and
Australia25,26 advocate the use of very low calorie/energy diets for
weight management, but recommend these should be delivered
in medical settings, with close medical monitoring.
At present formula diets are not funded directly within routine
UK NHS care, whereas bariatric surgery is. In the 1970 s there was
concern about safety of ill-designed modified fasting diets.27
Beliefs that more intensive interventions and rapid weight loss
lead to greater weight regain, are not supported by evidence from
controlled trials. Comparison of weight regains, following either a
12 week rapid weight loss programme or a 36 week gradual
programme, found no difference in the proportion of weight
regained at 144 week follow-up.28 Effective strategies for long-
term weight-loss maintenance have been described.29,30 A study
conducted within routine NHS primary care29 found that an
810 kcal per day LELD was well accepted by 91 severely obese
participants (mean BMI 48 kg/m2), and by GP’s and nurses. Those
who attended had a mean weight loss of around 17 kg in
12 weeks. Critically around 33% of all 91 entrants maintained
415 kg weight loss at 12 months. The study was in people
without diabetes, but the present review would suggest that
results in those with T2DM would not differ greatly. One year
follow-up of patients with knee osteoarthritis also found that a
structured weight maintenance programme resulted in good
maintenance of weight loss.30
It is estimated that by 2025, without new interventions for
prevention of weight gain and obesity, five million people in the
UK will have diabetes, mostly T2DM (DiabetesUK.org). Despite the
recommendations in current clinical guidelines, there is no
realistic prospect of bariatric surgery being offered to most obese
people because of surgical and follow-up resource limitations. In
addition, many people will not agree to surgery. New weight
management approaches are required for obese people with
T2DM that can be implemented in routine care, where most of
these people are managed. The present results suggest that the
weight loss phase of weight management can be achieved by a
period of ‘Total Diet Replacement’ (TDR), using micronutrient-
complete formula diets. This approach towards the SIGN weight loss
target of 415 kg (enough to reverse most recent onset T2DM), in
many cases is more cost-effectiveness than bariatric surgery.29
Most published studies do not adequately describe whether
adverse events were sought systematically, or simply reported on
an ad-hoc basis. Future research should include systematic data
collection. At present there is no evidence for serious adverse
events, and no specific medical monitoring is necessary except for
withdrawal or dose reduction of hypoglycaemic, diuretic or anti-
hypertensive drugs.
LIMITATIONS
This systematic review was limited by the very small number of
published studies, using a range of TDR methods, which directly
compared weight losses in people with and without T2DM. There
was substantial heterogeneity in the studies included, although
due to the limited number of studies subgroup analysis could not
be conducted to explore heterogeneity. Differences in diets (that
is, different calorie provisions across VLCD and LELD) and in
particular the very different study durations probably explain
much of the statistical heterogeneity. We therefore expressed the
results as kg lost per week, to reduce the effect of study duration.
There was no clear pattern to suggest different rates of weight loss
between VLED and LELD, despite different prescribed energy
deficits, indicating differences in compliance. This supports the
conclusion of Christensen et al.21 that weight losses are similar on
VLED or LELD. Heterogeneity may also have arisen from
differences in prescribed medications and other aspects of
diabetes care between the studies included. Despite the hetero-
geneity, the results from the different studies remain rather similar
both within and between the patient groups, which provides
some confidence that there is no important difference in the
weight loss responses of T2DM and non-diabetic people when
treated with a formula ‘Total Diet Replacement’. Future studies
should include more complete data on clinical details (for
example, medications) and complete data on the outcomes for
all entered subjects. The extent of data among people with T2DM
does not permit assessment of any diabetes-specific safety issues.
CONCLUSION
These data demonstrate that weight losses with VLCD or LELD are
very similar, and that weight losses, following interventions of
4–52 weeks duration, are no different for obese people with or
without T2DM. This result is novel, as most published studies of
diet and lifestyle interventions have shown less weight loss
among subjects with diabetes. It provides a firm baseline on which
Figure 2. Meta-analysis (WMD) of studies comparing weight losses in those with type 2 diabetes and non-diabetic subjects.
Weight loss in obese patients with and without T2DM
WS Leslie et al
100
International Journal of Obesity (2017) 96 – 101
the use of LELD may be further developed to achieve new weight-
loss targets of 415–20% for those with severe and medically
complicated obesity. Further research is warranted to evaluate the
delivery of more intensive, and better sustained, non-surgical
weight-management approaches for routine NHS application,
which could offer great benefit to people with T2DM.
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